Creative Planning
OREX

Creative Planning’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Creative Planning’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-126
Closed – – 4705
2017
Q2 		$0 Buy
126
+5
+4% +$15 ﹤0.01% 5111
2017
Q1 		$0 Sell
121
-150
-55% -$592 ﹤0.01% 5171
2016
Q4 		$0 Sell
271
-51,392
-99% -$121K ﹤0.01% 5125
2016
Q3 		$172K Buy
51,663
+644
+1% +$2.43K ﹤0.01% 1488
2016
Q2 		$219K Buy
51,019
+6,625
+15% +$30K ﹤0.01% 1214
2016
Q1 		$250K Buy
44,394
+29,788
+204% +$387K ﹤0.01% 1109
2015
Q4 		$251K Buy
14,606
+11,080
+314% +$264K ﹤0.01% 1080
2015
Q3 		$74K Buy
3,526
+2,257
+178% +$77.3K ﹤0.01% 1779
2015
Q2 		$63K Buy
1,269
+1,099
+646% +$65.7K ﹤0.01% 1019
2015
Q1 		$13K Sell
170
-51
-23% -$3.16K ﹤0.01% 3060
2014
Q4 		$13K Buy
221
+101
+84% +$5.07K ﹤0.01% 2994
2014
Q3 		$5K Hold
120
– – ﹤0.01% 3358
2014
Q2 		$7K Hold
120
– – ﹤0.01% 3090
2014
Q1 		$8K Sell
120
-20
-14% -$1.35K ﹤0.01% 2899
2013
Q4 		$8K Sell
140
-280
-67% -$15.7K ﹤0.01% 2695
2013
Q3 		$26K Hold
420
– – ﹤0.01% 1952
2013
Q2 		$25K Buy
+420
New +$25.8K ﹤0.01% 1811

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Creative Planning's OREX Position: Q3 2017 in Review

Creative Planning sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 126 shares.

Creative Planning first reported a position in OREX in Q2 2013 and held it in 17 quarters. The position peaked at $251K in Q4 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Creative Planning reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 126 Orexigen Therapeutics, Inc. shares in Q3 2017.
  • Creative Planning first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 17 quarters.
  • Creative Planning's Orexigen Therapeutics, Inc. position peaked at $251K in Q4 2015.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.